S&P 500 Futures
(0.23%) 5 118.00 points
Dow Jones Futures
(0.06%) 38 748 points
Nasdaq Futures
(0.67%) 17 725 points
Oil
(0.10%) $83.44
Gas
(0.22%) $1.816
Gold
(-0.30%) $2 335.10
Silver
(0.10%) $27.39
Platinum
(0.14%) $924.10
USD/EUR
(0.16%) $0.936
USD/NOK
(0.15%) $10.92
USD/GBP
(0.14%) $0.804
USD/RUB
(-0.71%) $92.53

Realtime updates for Biomarin Pharmaceutical [BMRN]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Upcoming Earnings Alert

Quarter results today
(amc 2024-04-24)

Expected move: +/- 3.57%

BUY
71.43%
return 12.38%
SELL
36.00%
return 5.68%
Last Updated23 Apr 2024 @ 16:00

2.87% $ 92.06

BUY 763 min ago

@ $91.96

Issued: 23 Apr 2024 @ 14:56


Return: 0.11%


Previous signal: Apr 23 - 09:30


Previous signal: Sell


Return: 2.14 %

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 16:00):
Profile picture for Biomarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease...

Stats
Today's Volume 1.27M
Average Volume 1.40M
Market Cap 17.47B
EPS $0 ( 2024-02-22 )
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E 105.82
ATR14 $2.23 (2.42%)
Insider Trading
Date Person Action Amount type
2024-04-12 Bienaime Jean Jacques Buy 20 000 Common Stock
2024-04-11 Bienaime Jean Jacques Sell 20 000 Common Stock
2024-04-12 Bienaime Jean Jacques Sell 20 000 Common Stock
2024-04-11 Bienaime Jean Jacques Sell 20 000 Stock Option (Right to Buy Common Stock)
2024-04-12 Bienaime Jean Jacques Sell 20 000 Stock Option (Right to Buy Common Stock)
INSIDER POWER
25.85
Last 93 transactions
Buy: 972 265 | Sell: 563 201

Volume Correlation

Long: -0.42 (neutral)
Short: -0.63 (weak negative)
Signal:(61) Neutral

Biomarin Pharmaceutical Correlation

10 Most Positive Correlations
MMAC0.923
RMRM0.916
FREQ0.89
ABST0.889
IMPL0.889
SGBX0.887
TTOO0.887
INFI0.885
SBBP0.884
CFV0.884
10 Most Negative Correlations
APOP-0.956
ICON-0.907
RDUS-0.893
MIND-0.88
TRMD-0.879
WRLD-0.878
SYKE-0.875
SOUN-0.873
MGTX-0.873
FEYE-0.869

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Biomarin Pharmaceutical Correlation - Currency/Commodity

The country flag -0.61
( weak negative )
The country flag -0.55
( weak negative )
The country flag 0.00
( neutral )
The country flag -0.35
( neutral )
The country flag 0.46
( neutral )
The country flag 0.46
( neutral )

Biomarin Pharmaceutical Financials

Annual 2023
Revenue: $2.42B
Gross Profit: $1.84B (76.15 %)
EPS: $0.890
Q4 2023
Revenue: $646.21M
Gross Profit: $510.73M (79.03 %)
EPS: $0.110
Q3 2023
Revenue: $585.97M
Gross Profit: $445.54M (76.04 %)
EPS: $0.210
Q2 2023
Revenue: $594.60M
Gross Profit: $450.92M (75.84 %)
EPS: $0.300

Financial Reports:

No articles found.

Biomarin Pharmaceutical

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators